EUVIMEDEUVIMED entdecken
Crossref

Box–Behnken-designed nanostructured lipid carriers of xanthohumol for enhanced cellular uptake in human lung cancer cell line A549: formulation, optimization, characterization, and cytotoxicity assessment

Shubham Singh, Himani Sharma, Madan Kumar Arumugam, Gaurav Gupta, Nisha Panth, Mangesh Pradeep Kulkarni, Gabriele De Rubis, Brain G Oliver, Keshav Raj Paudel, Narendra Kumar Pandey, Md Sadique Hussain, Popat S Kumbhar und 3 weitere

Medical Oncology · 2025

DOI: 10.1007/s12032-025-03087-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, 2025. Verfasst von Shubham Singh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, 144411, India. Hauptthemen laut MEDLINE: Flavonoids, Propiophenones, Lung Neoplasms, Drug Carriers. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present research aims to develop and optimize nanostructured lipid carriers (NLCs) of Xanthohumol (Xn) for treating lung cancer (LC). Xn packed NLCs were successfully prepared by hot high-pressure homogenization in conjunction with the ultrasonication method and optimized using a pseudo-ternary phase diagram followed by the Box-Behnken design (BBD). The NLCs were solidified using rotary evaporation followed by tray drying/vacuum drying. Mannitol was used for the solidification of L-Xn-NLCs. The BBD was operated using 3 factors and 3 levels for optimization of the formulation. The dependent variables were zeta potential (R1), particle size (R2), and drug entrapment efficiency (R3), while the independent variables were Beeswax (A), Lauroglycol-90 (B), and Tween 80 (C). The optimized liquid NLCs (L-Xn-NLCs) showed particle size (PS) of 101.60 ± 1.47 nm, polydispersity index (PDI) of 0.772 ± 0.029, zeta potential (ZP) of - 25.6 mV, and an entrapment efficiency (% EE) of 97.72 ± 1.05%. As a result, NLCs have a higher drug encapsulation efficiency. After drying, followed by reconstitution, the solid NLCs (S-Xn-NLCs) showed PS of 278 nm, PDI of 0.22, ZP of - 44.3 mV, and EE% of 95.5. The results of SEM and PXRD revealed the complete adsorption of S-Xn-NLCs on the surface of mannitol. The in vitro drug release and in vitro MTT assay were performed on A549 LC cells to evaluate the anticancer efficacy of S-Xn-NLCs. In 24 h, the L-Xn-NLCs, S-Xn-NLCs, and pure drug suspension had a cumulative drug release rate of 80.09 ± 0.8%, 79.8%, and 40 ± 1.1%, respectively. It was found that both pure Xn and S-Xn-NLCs reduced the proliferation of A549 cell lines at 28.21 µM, 56.42 µM, 84.63 µM, 112.84 µM, and 141 µM. However, S-Xn-NLCs exerted higher reduction in proliferation than pure Xn. The pure Xn and the S-Xn-NLCs showed anticancer potential against A549 cell lines and the IC50 was found to be 140.186 µM for the pure Xn and 84.63 µM for the S-Xn-NLCs. The S-Xn-NLCs showed higher cytotoxicity potential to A549 cells as compared to the pure Xn. Thus, it was concluded that the optimized NLCs showed very good efficacy against LC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlavonoidsPropiophenonesLung NeoplasmsDrug CarriersNanostructuresLipidsHumansA549 CellsParticle SizeCell SurvivalDrug Liberation

Stichwörter der Autor:innen

A549 cellsBox–Behnken design (BBD)CytotoxicityLung cancer (LC)Xanthohumol (Xn)

Substanzen

FlavonoidsPropiophenonesxanthohumolDrug CarriersLipids

Autor:innen und Institutionen

  • Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
  • School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
  • Cancer Biology Lab, Centre for Molecular and Nanomedical Sciences, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
  • Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.
  • Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
  • Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia.

Zitieren

APA

Singh, S., Sharma, H., Arumugam, M. K., Gupta, G., Panth, N., Kulkarni, M. P., De Rubis, G., Oliver, B. G., Paudel, K. R., Pandey, N. K., Hussain, M. S., Kumbhar, P. S., Disouza, J., Dua, K., & Singh, S. K. (2025). Box–Behnken-designed nanostructured lipid carriers of xanthohumol for enhanced cellular uptake in human lung cancer cell line A549: formulation, optimization, characterization, and cytotoxicity assessment. Medical Oncology. https://doi.org/10.1007/s12032-025-03087-4

Vancouver

Singh S, Sharma H, Arumugam MK, Gupta G, Panth N, Kulkarni MP, et al. Box–Behnken-designed nanostructured lipid carriers of xanthohumol for enhanced cellular uptake in human lung cancer cell line A549: formulation, optimization, characterization, and cytotoxicity assessment. Medical Oncology. 2025. doi:10.1007/s12032-025-03087-4

BibTeX
@article{Singh2025,
  author = {Singh, Shubham and Sharma, Himani and Arumugam, Madan Kumar and Gupta, Gaurav and Panth, Nisha and Kulkarni, Mangesh Pradeep and De Rubis, Gabriele and Oliver, Brain G and Paudel, Keshav Raj and Pandey, Narendra Kumar and Hussain, Md Sadique and Kumbhar, Popat S and Disouza, John and Dua, Kamal and Singh, Sachin Kumar},
  title = {Box–Behnken-designed nanostructured lipid carriers of xanthohumol for enhanced cellular uptake in human lung cancer cell line A549: formulation, optimization, characterization, and cytotoxicity assessment},
  journal = {Medical Oncology},
  year = {2025},
  doi = {10.1007/s12032-025-03087-4}
}
Kostenlos starten →